Cervicovaginal fluid proteomic analysis to identify potential biomarkers for preterm birth.
Spontaneous preterm birth (SPTB) is a leading cause of neonatal morbidity and mortality. Early identification of at-risk women by reliable screening tests could reduce the SPTB rate, but conventional methods such as obstetrical history and maternal cervical length screening identify only a minority of SPTB cases. Cervicovaginal fluid (CVF) might prove to be a useful, readily available biological fluid for identifying SPTB biomarkers. To identify CVF biomarkers of early SPTB in a high-risk cohort of pregnant women with a history of SPTB using targeted and shotgun proteomic analyses. A nested case control study (cases = SPTB <34 weeks in the current pregnancy; controls = spontaneous labor and delivery at 39-41 weeks) was performed using CVF samples collected at three study visits (100/7-186/7 weeks, 190/7-236/7 weeks, and 280/7-316/7 weeks). All participants had a history of at least one prior SPTB. Targeted proteomic analysis was performed using a stable-isotope labeled proteome (SILAP) derived from endocervical and vaginal mucosal cells. This served as a standard to quantitate candidate protein levels in individual CVF samples from the second and third study visits using liquid chromatography-multiple reaction monitoring mass spectrometry. The ratio of endogenous peptide area/SILAP-derived peptide area was used to measure levels of 42 peptides in 22 proteins. In order to maximize biomarker discovery in the CVF samples, shotgun proteomic analysis also was performed utilizing liquid chromatography and ion trap mass spectrometry. A validation study was performed in second-trimester CVF samples from an independent study group (12 SPTB cases, 19 term delivery controls) using enzyme-linked immunosorbent assay (ELISA) for five proteins expressed at higher levels in SPTB cases compared to controls in targeted or shotgun proteomic analyses. For targeted proteomics, CVF samples from 33 cases and 32 controls at 190/7-236/7 weeks, and 16 cases and 14 controls at 280/7-316/7 weeks from the same pregnancies, were analyzed. When samples were compared between cases and controls, the relative abundance of five proteins was greater (P=0.02-0.05) in cases at both visits, while the relative abundance of one protein was lower (P=0.03) in cases at both visits. For shotgun proteomics analyses, CVF samples were pooled for nine SPTB cases and nine term delivery controls at each study visit. Shotgun proteomics yielded 28 proteins that were detected at levels >2x higher and one protein that was detected at a level <0.5X lower in SPTB cases compared to controls at all three study visits. Validation ELISA for five proteins that were detected at higher levels in CVF samples from SPTB cases compared to term delivery controls in proteomics analyses did not demonstrate statistically significant differences between SPTB cases and controls. Potential biomarkers of SPTB were identified by targeted and shotgun proteomics analyses in CVF samples from high-risk, asymptomatic women. Many of the proteins detected at higher levels in CVF samples from SPTB cases are extracellular matrix proteins and/or regulate cell membrane physiology. These proteins have substantial biological interest, but validation ELISA for five of these proteins did not yield clinically useful biomarkers for SPTB.